Trial record 2 of 16 for:    Avanir

Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) (PRISM II)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Avanir Pharmaceuticals
Sponsor:
Collaborator:
OptumInsight Life Sciences
Information provided by (Responsible Party):
Avanir Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01799941
First received: February 25, 2013
Last updated: March 13, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)